Potential Role for the Metnase Transposase Fusion Gene in Colon Cancer through the Regulation of Key Genes

Panagiotis Apostolou, Maria Toloudi, Eleni Kourtidou, Georgia Mimikakou, Ioanna Vlachou, Marina Chatziioannou, Vasiliki Kipourou, Ioannis Papasotiriou*

Research Genetic Cancer Centre Ltd (R.G.C.C. Ltd), Filotas, Florina, Greece

Abstract
The Metnase fusion gene consists of a SET histone methyltransferase domain and a transposase domain from Mariner transposase. This transposable element is involved in chromosome decatenation, enhances DNA repair, promotes foreign DNA integration, and assists topoisomerase II function. This study investigates the role of Metnase in colon cancer homeostasis and maintenance of the stemness phenotype in colon cancer stem cells (CSCs). Silencing of Metnase was performed in human cancer cell lines before and after treatment with cisplatin, and in colon CSCs. Subsequent changes in the expression of genes involved in repair mechanisms, DNA synthesis, topoisomerase II function, and metastasis as well stemness transcription factors were studied with RT-qPCR experiments. Cellular viability and apoptosis were evaluated by flow cytometry. The results suggest that Metnase influences the expression of many genes involved in the above processes. Furthermore, Metnase levels appear to impact upon expression of NANOG, OCT3/4, and SOX2. Suppression of Metnase also led to an increase in apoptosis. Therefore, Metnase may possess an important role in DNA repair, topoisomerase II function, and the maintenance of stemness during colon cancer development.

Citation: Apostolou P, Toloudi M, Kourtidou E, Mimikakou G, Vlachou I, et al. (2014) Potential Role for the Metnase Transposase Fusion Gene in Colon Cancer through the Regulation of Key Genes. PLoS ONE 9(10): e109741. doi:10.1371/journal.pone.0109741

Editor: Javier S Castresana, University of Navarra, Spain

Copyright: © 2014 Apostolou et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting information files.

Funding: All the authors are employees of Research Genetic Cancer Centre Ltd (R.G.C.C. Ltd), and received salary from the R.G.C.C. Ltd, which funded this study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: All the authors are employees of Research Genetic Cancer Centre Ltd (R.G.C.C. Ltd). The R.G.C.C. Ltd funded this study. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all PLOS ONE policies on sharing data and materials.

* Email: office@rgcc-genlab.com

Introduction
Metnase is a fusion gene with a SET histone methyltransferase domain and a Mariner transposase domain. Several of the main functions of HsMar1 transposase are shared with Metnase [1]. Metnase is a non-homologous end-joining (NHEJ) repair protein [2], and is involved in many cellular processes including mediation of foreign DNA integration, chromosome decatenation [3], and DNA repair [4] and replication [5]. Metnase further mediates resistance to topoisomerase II inhibitors through an interaction with topoisomerase (DNA) II alpha (TOP2A) [6]. These established roles in combination with recent experimental data suggest that Metnase may have a crucial role in cancer development and progression, which could be exploited during cancer treatment.

Colorectal cancer is the second leading cause of cancer in women, the third in men, and the fourth most common cause of cancer death overall [7]. The use of platinum-based chemotherapeutics is commonplace in treatment regimes. However, many patients either possess or develop resistance to these compounds [8]. Furthermore, cancer stem cells (CSCs) have the capacity for self-renewal and are resistance to chemotherapy and radiation treatment [9]. Therefore, improvements to current treatment strategies are required.

The present study examines the relationship between Metnase gene expression and colorectal cancer development. As transposable genetic elements are implicated in genome rearrangement, they may regulate many transcription factors. These factors could in turn regulate genes that are involved in resistance, metastasis, or apoptosis. An evaluation of the complement of genes that are affected by Metnase as well as their correlation with basic cellular activities may enhance our understanding of how Metnase influences cancer development. Such knowledge could also contribute to improvements in cancer treatment programs.

This study examines the expression levels of several genes important in cellular development and DNA synthesis and repair before and after knockdown of Metnase by siRNA. These genes were DNA excision repair protein (ERCC1), dipeptidylpeptidase IV (CD26), Met proto-oncogene (cMET), TOP2A, topoisomerase (DNA) II beta (TOP2B), thymidylate synthase (TYMS) and DNA (cytosine-5')-methyltransferase 1 (DNMT1). The effect of Metnase silencing was also investigated in a colorectal cancer cell line following treatment with cisplatin. While oxaliplatin is mainly used in clinical settings, here we wished to investigate the role of Metnase in a resistant cell line. According to experiments that were previously performed in the HCT-116 cell line, we have found that more resistance mechanisms develop following treatment with cisplatin. Finally, a potential relationship between Metnase and maintenance of the stemness phenotype of colon CSC was investigated by silencing Metnase and measuring levels

Received June 18, 2014; Accepted September 8, 2014; Published October 15, 2014
of NANOG, POU class 5 homeobox 1 (OCT3/4), and SRY (sex determining region Y)-box 2 (SOX2), all of which have crucial roles in the maintenance of stemness [10,11].

Material and Methods

Cell Culture

Human colon CSCs (36112-39P; Celprogen, CA; USA) and HCT-116 Human colon carcinoma cells (91091005; ECACC, UK) were cultured in appropriate growth medium (M36112-39PS; Celprogen, and D5546; Sigma-Aldrich, Steinheim; Germany) supplemented with 10% FBS (10270-106; Gibco, NY; USA) in 25 cm² flasks (E36102-29P-T25; Celprogen, and 430639; Corning, NY; USA) at 37°C in a 5% CO₂ environment. HCT-116 cells were also treated with 1 µg/mL cisplatin (P4394; Sigma-Aldrich) for more than 10 passages and cultured in a similar manner.

siRNA transfection

During the exponential growth phase, cells were plated in 24-well plates (E36112-39; Celprogen, and 331.836; Sarstedt, Numbrecht; Germany) and transfected with Metnase-specific siRNA using Lipofectamine 2000 Reagent (11668-027; Invitrogen, CA; USA), according to manufacturer’s instructions. The siRNA (5'-UAAACCCUCACCCGACAUUU-3') was designed in accordance with the rules of Reynolds et al. [12] and subjected to BLAST analysis to ensure specificity. Following 48 h incubation, cells were harvested by trypsinization (25000-072; Invitrogen). Vehicle-alone and non-specific siRNA controls were included. The mRNA knockdown was calculated relative to the non-targeting control siRNA in each experiment. Experiments were repeated three times in triplicate. The expression level of the gene of interest and percentage knockdown was calculated using the comparative Ct method:

\[ \Delta Ct = Ct_{\text{target}} - Ct_{18S} \]
\[ \Delta \Delta Ct = \Delta Ct_{\text{siRNA treated}} - \Delta Ct_{\text{siRNA non- treated}} \]
\[ \text{Relative expression level} = 2^{-\Delta \Delta Ct} \]
\[ \% \text{ KD} = 100 \times (1 - 2^{-\Delta \Delta Ct}) \]

Evaluation of cells

Cells were evaluated by cellular and molecular assays. Cellular assays were based on the ability of CSCs to form microspheres. The cultures have previously been evaluated by gene expression assays were based on the ability of CSCs to form microspheres.

Molecular Assays

RNA from cell cultures was extracted using the RNasy mini kit (74105; Qiagen, Hilden; Germany). RNA samples were evaluated both spectrophotometrically and by agarose gel electrophoresis visualization of the 18S–28S bands. Genomic DNA was removed by using RNeasy-Free DNase (79254; Qiagen). Subsequently, 1 µg of this RNA was used as a template for cDNA synthesis with an iScript cDNA synthesis kit (1708891; Bio-Rad, CA; USA). Real-time PCR, was performed using the iQ SYBR Green Supermix (1725124; Bio-Rad) with each sample in triplicate. Specific primers for each marker and for an endogenous control gene (18S rRNA) were designed with Genomics Expression 1.1 software [13–16]. Primer sequences were analyzed by BLAST to exclude those who amplified undesired genes. Table 1 shows the sequences of the primers.

The PCR reaction program was as follows; initial denaturation at 95°C, 50 cycles of denaturation at 95°C for 10 sec followed by annealing at 59°C for 30 sec. A final extension step was performed at 72°C for 10 min followed by melting curve analysis. Data were analyzed according to the method of Livak and Schmittgen [17]. In all PCR reactions, appropriate controls were used. The positive control was cDNA from a Universal Human Reference RNA (740000-41; Agilent, CA; USA) and negative controls were no-template, no-enzyme controls as well as Human genomic DNA (G304A; Promega, WI; USA). Finally, a no-reverse transcription control was used in cDNA synthesis. The standard curves of all primers are presented in figure S1.

Flow cytometry

Cells were stained with PE Annexin V and 7-Amino-Actinomycin (559763; BD Biosciences, CA; USA) for 15 min followed by resuspension in 0.5 mL sheath fluid (8346859; Beckman Coulter, Nyon; Switzerland) and flow cytometry analysis of more than 50,000 events. The data were analyzed with FCS Express Software (DeNovo). In each case appropriate positive and negative controls were used.

Statistical Analysis

The quantitative polymerase chain reaction (qPCR) results were assessed according to the Kolmogorov-Smirnov test; all samples had normal distribution. Median values were used for the analysis. Mann-Whitney tests were also performed on the qPCR data [18,19]. All experiments were performed in triplicate three times. A p value <0.05 was considered significant.

Results

Gene Expression

Silencing of Metnase expression by siRNA was up to 65% efficient in HCT-116 cells, 52% in HCT-116 cells treated with cisplatin, and 40% in colon CSCs (Figures 1–3). Suppression of Metnase in HCT-116 cells led to an increase in CD26 gene expression and a decrease in the expression of all other genes measured. This decrease was higher for TOP2A, TOP2B, ERCC1, TYMS, and DNMT1, ranging from 25–35%, while a minor fall of 5–10% of cMET expression was observed (Figure 1). ERCC1 is involved in DNA repair processes, and its expression has been linked with sensitivity of this cell line to platinum compounds [20].

We observed similar results in HCT-116 cells treated with cisplatin. The enhanced decrease in topoisomerase II gene expression seen following Metnase silencing in HCT-116 cells treated with cisplatin compared with those not treated is also remarkable. TYMS and DNMT1 expression were decreased by up to 60%, while TOP2B expression was decreased by 18–35% and cMET by almost 40%. ERCC1 levels were not affected, indicating that treatment with cisplatin for many passages leads to development of resistance mechanisms (Figure 2).

Following silencing of Metnase in colon CSCs, the only gene measured that demonstrated increased expression was CD26. A decrease was observed for the TYMS and TOP2A genes, while the expression of ERCC1, cMET, and TOP2B appeared unaffected (Figure 3). These results demonstrated that CSCs are...
more resistant to chemotherapeutics than differentiated cancer cells. Overall, the expression levels of genes regarded as stemness transcription factors were decreased following silencing of Metnase expression in CSCs. This decrease in expression was up to 60% for SOX2, 40% for OCT3/4 and 45% for NANOG (Figure 4).

Cell Viability-Apoptosis

The number of cells undergoing apoptosis as determined by flow cytometry was doubled following suppression of Metnase expression in both HCT-116 and HCT-116 + cisplatin cells. An increase in the number of dead cells was also observed. However, cellular viability was not significantly changed in colon CSCs, cell viability decreased following Metnase silencing, but no change in the number of cells undergoing apoptosis was observed. The population of dead cells was higher in the HCT-116 cell line than in the other two. This could be attributable to the resistance mechanisms that develop in the cisplatin-treated cell line, or such mechanisms may natively exist in CSCs. Table 2 depicts data for each cell line.

Discussion

The Metnase fusion gene methylates histone H3 at lysine 36 and possesses many characteristics of a transposase, including terminal inverted repeat sequence-specific DNA binding and DNA looping [21]. However, it cannot complete transposition reactions. Through its methylation activity, Metnase is implicated in DNA repair by the NHEJ pathway. This repair activity requires an interaction with Pso4 [22]. The ERCC1 protein is also involved through nucleotide excision repair [23]. This study suggests the existence of a relationship between ERCC1 expression and Metnase. Specifically, suppression of Metnase led to decreased expression of the repair gene, however, this decrease was less pronounced when cells were treated with cisplatin. This further supports a role for ERCC1 in cisplatin therapy.

TOP2A is the primary decatenation enzyme, resolving tangled or catenated chromatids [24]. This study also confirms that Metnase mediates resistance to topoisomerase II α inhibitors, with gene expression of TOP2A affected more than other genes following Metnase knockdown. This decrease was enhanced in cells treated with cisplatin and in CSCs. Furthermore, suppression of both TOP2A and TOP2B was observed, indicating that

---

**Table 1. Primer pairs that were used in qPCR.**

| Gene   | Primer       | Sequence (5’-3’)       | Accession No | Amplicon Length | Location | Splice Variant |
|--------|--------------|------------------------|--------------|-----------------|----------|---------------|
| 18S rRNA Forward | TGCCCATCAAACCTTTGGGATGATGTC | NR_003286 | 112bp | 22p12 | – |
| 18S rRNA Reverse | GTTGGATGGTAGGCGTTGCCATTCA | NM_024865 | 138bp | 12p13.31 | Transcript variant 1 |
| NANOG Forward | TGAGATGCGTCACACGGAGACTG | NM_001173531 | 97bp | 6p21.31 exon 5 | Transcript variant 3 |
| NANOG Reverse | GGTTGATCCTTCCT GGAGACTG | NM_001243723 | 123bp | 3p26.1 exon 3 | Transcript variant 2 |
| OCT3/4 Forward | GTGCCATTGGCCTCCTAGAAATG | NM_001173531 | 97bp | 6p21.31 exon 5 | Transcript variant 3 |
| OCT3/4 Reverse | TGCCCATCAAACCTTTGGTTCGTC | NM_001173531 | 91bp | 3p26.3-3q27 exon 1 | – |
| SOX2 Forward | CAACGGAGCTACAGCATGATGTC | NM_001173531 | 91bp | 6p21.31 exon 5 | Transcript variant 2 |
| SOX2 Reverse | GGGTGGGATGCGTTGGAGGACTG | NM_001173531 | 91bp | 6p21.31 exon 5 | Transcript variant 3 |
| Metnase Forward | GCAGCAAGAAACAACCTGCAACATTC | NM_001173531 | 123bp | 3p26.1 exon 3 | Transcript variant 2 |
| Metnase Reverse | AGGCCAAGGACCAACCATTC | NM_001173531 | 123bp | 3p26.1 exon 3 | Transcript variant 2 |
| ERCC1 Forward | GCTACCAACCTGCACCCAGACT | NM_001166049 | 152bp | 19q13.32 exon 5 | Transcript variant 3 |
| ERCC1 Reverse | GCAGCCGCCCAGGACCATACAT | NM_001166049 | 152bp | 19q13.32 exon 5 | Transcript variant 3 |
| CD26 Forward | GAGATTGCTCGCTCTGGCTTCGTC | NM_001173531 | 127bp | 2q24.3 exon 16-17 | – |
| CD26 Reverse | TGGAGGGGATCTGGGACACATTC | NM_001173531 | 127bp | 2q24.3 exon 16-17 | – |
| cMET Forward | AACAGGTGCAAAGCTGCGAGTGTCATTC | NM_001173531 | 95bp | 7q31 exon 19 | Transcript variant 2 |
| cMET Reverse | GCAGCCCAAGGACCAACCATTC | NM_001173531 | 95bp | 7q31 exon 19 | Transcript variant 2 |
| TOP2A Forward | TGGTCTGAGATGATGCTGCTATC | NM_001067 | 120bp | 17q21-q22 exon 16 | – |
| TOP2A Reverse | GGAGCGAGGTACCTGCTGCTGTC | NM_001067 | 120bp | 17q21-q22 exon 16 | – |
| TOP2B Forward | CCAAGAGAGGGCCCAAAAACAGA | NM_001068 | 151bp | 3p24 exon 34 | – |
| TOP2B Reverse | CGCCCTCCATTCTGAGGACAGAT | NM_001068 | 151bp | 3p24 exon 34 | – |
| TYMS Forward | TCTGGTGACAACACGGCTGGCTTCGTC | NM_001071 | 123bp | 8p11.32 exon 2 | – |
| TYMS Reverse | CATTGACGATCCAGATTTCAC | NM_001071 | 123bp | 8p11.32 exon 2 | – |
| DNMT1 Forward | CTGGAGCCACCAGAGCCGCTATTCAAT | NM_001130823 | 126bp | 19p13.2 exon 16 | Transcript variant 1 |
| DNMT1 Reverse | CGCCCTCATCTCCTAAAGCGCAAC | NM_001130823 | 126bp | 19p13.2 exon 16 | Transcript variant 1 |
Metnase could be a target for combination chemotherapy with topoisomerase II inhibitors. Expression of dipeptidyl peptidase IV (CD26) is correlated with colon cancer progression and CD26+CSCs have been identified in human colorectal cancer. Here, CD26 gene expression was increased in all cases of Metnase knockdown. This enzyme is associated with immune regulation, signal transduction and apoptosis. This indicates that Metnase is involved in regulating apoptosis, perhaps through an interaction with CD26 [23].

The cMET proto-oncogene encodes the hepatocyte growth factor receptor and is closely associated with cancer development. Aberrant activation of cMET leads to tumor growth, angiogenesis and finally metastasis. In contrast to normal stem cells, CSCs express cMET, facilitating cancer persistence and spread [20].

Figure 1. Metnase regulates gene expression in colon CSCs. Relative gene expression of transcription factors in Colon CSCs following Metnase knockdown. The percentage of Metnase knockdown reached 40%. The ΔΔCt method was used to perform the analysis. Each bar represents the average of the Ct values. The assays were performed in triplicate and a p-value <0.05 was considered significant. In the control sample the average value is 1.00 indicating that there is no change in gene expression. Values >1 indicate an increase in gene expression while values <1 indicate a decrease in gene expression. The conditions for subsequent experiments were the same.

doi:10.1371/journal.pone.0109741.g001

Figure 2. Metnase regulates gene expression in HCT-116 cell line. Relative gene expression of transcription factors in HCT-116 cells following Metnase knockdown. The percentage of knockdown reached 65%.

doi:10.1371/journal.pone.0109741.g002
Negative feedback regulation of MET-dependent invasive growth by Notch has been demonstrated in Drosophila [27], and Notch genes also regulate MET in humans [28]. However, this study found no association of cMET levels with those of Metnase transposase.

We observed a relationship between Metnase and two genes important in DNA homeostasis, TYMS and DNMT1. Gene expression of both was decreased in all cell lines following silencing of Metnase expression. TYMS generates thymidine monophosphate, which is subsequently phosphorylated to thymidine triphosphate for use in DNA synthesis and repair [29]. DNMT1 is an enzyme involved in the regulation of methylated cytosine residues, and its aberrant methylation is associated with cancer development [30]. This decrease in levels of TYMS and DNMT1 was enhanced in cells treated with cisplatin. Therefore, Metnase may be implicated in cancer development and establishment through interaction with or influence of several enzymes that possess key roles in cancer.

We also investigated the relationship between Metnase and transcription factors essential for maintaining stemness. CSCs are

**Figure 3.** Metnase regulates gene expression in HCT-116 cells treated with cisplatin. Relative gene expression of transcription factors in HCT-116 cells treated with cisplatin, after Metnase knockdown. The percentage of knockdown reached 52%.
doi:10.1371/journal.pone.0109741.g003

**Figure 4.** Metnase regulates gene expression of stemness markers. Relative gene expression analysis of the stemness transcription factors NANOG, OCT3/4, and SOX2 following Metnase knockdown.
doi:10.1371/journal.pone.0109741.g004
defined by the ability to self-renew, differentiate, and proliferate. CSCs express many transcription factor markers, but the most important are NANOG, OCT3/4 and SOX2 gene. NANOG is expressed in ESCs and has a key role in maintaining pluripotency. Its overexpression causes self-renewal in ESCs, while its absence leads to differentiation [31,32]. To maintain stemness, the presence of two further transcription factors, OCT3/4 and SOX2 is required. OCT3/4 expression is also associated with the presence of two further transcription factors, OCT3/4 and SOX2. SOX2 and together these two proteins bind to DNA. SOX2 is required. OCT3/4 expression is also associated with decreased gene expression of all transcription factors, indicating that Metnase may be involved in cancer establishment as well as in cancer development and progress.

Cellular viability appeared unaffected by Metnase knockdown. The cisplatin-treated cell line appeared to have fewer dead cells in compare with the non-treated cell line. Similar findings were obtained using colon CSCs. This further supports the resistance in cancer stem-like cells and high-grade oral squamous cell carcinoma. Further studies are needed to elucidate the details of these interactions.

Table 2. Percentage of dead cells and cells undergoing apoptosis before and after Metnase Knockdown.

| Cell line          | Cells undergoing apoptosis (%) | Dead cells (%) |
|--------------------|--------------------------------|---------------|
| HCT-116 Control    | 2.03 (±0.20)                  | 8.32 (±0.43)  |
| HCT-116 Metnase Knockdown | 4.01 (±0.35)      | 10.74 (±0.55) |
| HCT-116 + CDDP Control | 1.23 (±0.17)                  | 2.77 (±0.22)  |
| HCT-116 + CDDP Metnase Knockdown | 2.67 (±0.15) | 3.96 (±0.30) |
| Colon CSCs Control | 1.9 (±0.15)                   | 1.36 (±0.12)  |
| Colon CSCs Metnase Knockdown | 1.55 (±0.26)      | 5.63 (±0.18)  |


doi:10.1371/journal.pone.0109741.t002

could be explained by the development of alternative apoptosis-evading mechanisms developing in the CSCs compared with the treated cell line.

This study identifies that the Metnase fusion gene is heavily involved in DNA repair mechanisms, DNA synthesis, topoisomerase II resistance, apoptosis, and the maintenance of the stemness phenotype in colon cancer. Further studies are needed to elucidate the details of these interactions.

Supporting Information

Figure S1 Standard Curves – Standard curves for all primers used. A: 18S rRNA, B: Metnase, C: ERCC1, D: cMET, E: CD26, F: TOP2A, G: TOP2B, H: TYMS, I: DNMT1, J: NANOG, K: OCT3/4, and L: SOX2. (TIF)

Author Contributions

Conceived and designed the experiments: PA MT IP. Performed the experiments: PA IP. Analyzed the data: PA IP. Contributed reagents/materials/analysis tools: EK IV GM VK MC. Wrote the paper: PA IP.

References

1. Liu D, Bischler J, Siddique A, Bossine N, Bigot Y, et al. (2007) The human SETMAR protein preserves most of the activities of the ancestral Homar transposase. Mol Cell Biol 27: 1125–1132.
2. Kim HS, Chen Q, Kim SK, Nickeloff JA, Hromas R, et al. (2014) The DNA Catalytic Motif is required for Metnase Functions in NHEJ Repair and Replication Restart. J Biol Chem.
3. Wray J, Williamson EA, Sheema S, Lee SH, Libby E, et al. (2009) Metnase mediates chromosome decatenation in acute leukemia cells. Blood 114: 1852–1858.
4. Williamson EA, Damiani L, Lezio A, Hu C, Hathaway H, et al. (2012) Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy. Cancer Res 72: 6200–6208.
5. Hromas R, Williamson EA, Fru S, Lee YJ, Park SJ, et al. (2012) Chk1 phosphorylation of Metnase enhances DNA repair but inhibits replication fork restart. Oncogene 31: 4245–4254.
6. Wray J, Williamson EA, Royce M, Shaheen M, Beck BD, et al. (2009) Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells. PLoS One 4: e5322.
7. Haggar F, Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22: 191–197.
8. Sahlberg SH, Spiegelberg D, Giimmelius B, Stenerlow B, Nestor M (2014) Evaluation of cancer stem cell markers CD133, CD44, CD124: association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One 9: e96261.
9. Tolouhi M, Apostolou P, Chatziioannou M, Papastoriou I (2011) Correlation between Cancer Stem Cells and Circulating Tumor Cells and Their Value. Case Rep Oncol 4: 44–54.
10. Chiao SH, Yu CC, Huang CY, Lin SC, Liu CJ, et al. (2008) Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 14: 4085–4095.
11. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, et al. (2011) Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer 104: 1410–1417.
12. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, et al. (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22: 326–330.
13. Wallace RB, Shaffer J, Murphy RF, Bonner J, Hinson T, et al. (1979) Hybridization of synthetic oligodeoxyribonucleotides to phi chi 174 DNA: the effect of single base pair mismatch. Nucleic Acids Res 6: 3543–3557.
14. Breslauer JK, Frank R, Blocker H, Marky LA (1986) Predicting DNA duplex stability from the base sequence. Proc Natl Acad Sci U S A 83: 3746–3750.
15. Rychlik W, Spencer WJ, Rhodes RE (1990) Optimization of the annealing temperature for DNA amplification in vitro. Nucleic Acids Res 18: 6409–6412.
16. Meinkoth J, Wahl G (1984) Hybridization of nucleic acids immobilized on solid supports. Anal Biochem 130: 267–284.
17. Lavak JK, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.
18. Stephens MA (1974) EDF Statistics for Goodness of Fit and Some Comparisons. Journal of the American Statistical Association. 69: 730–737.
19. Fay MP, Proschan MA (2010) Wilcoxon-Mann-Whitney or t-test? On assumptions for hypothesis tests and multiple interpretations of decision rules. Stat Surv 4: 1–39.
20. Kirschner K, Metlon DW (2010) Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30: 3223–3232.
21. Fru S, Williamson EA, De Haro LP, Brenneman M, Wray J, et al. (2011) Mediation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining. Proc Natl Acad Sci U S A 108: 540–545.
22. Beck BD, Park SJ, Lee YJ, Roman Y, Hromas RA, et al. (2008) Human Poi5 is a metnase (SETMAR)-binding partner that regulates metnase function in DNA repair. J Biol Chem 283: 9203–9209.
23. Liu GY, Qu QX, Mi RR, Qi J (2010) Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer. Zhonghua Zhong Liu Za Zhi 30: 184–187.
24. Schoeffler AJ, Berger JM (2005) Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem Soc Trans 33: 1465–1470.
25. Yu DM, Yao TW, Chowdhury S, Nadvi NA, Osborne B, et al. (2010) The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 277: 1126–1144.
26. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, et al. (2003) c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9: 1480–1488.
27. Stella MC, Trusolino L, Pennacchietti S, Comoglio PM (2005) Negative feedback regulation of Met-dependent invasive growth by Notch. Mol Cell Biol 25: 3982–3996.
28. Apostolou P, Teloudi M, Ioannou E, Kourtidou E, Chatziioannou M, et al. (2013) Study of the interaction among Notch pathway receptors, correlation with stemness, as well as their interaction with CD44, dipeptidyl peptidase-IV, hepatocyte growth factor receptor and the SETMAR transferase, in colon cancer stem cells. J Recept Signal Transduct Res 33: 353–358.
29. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, et al. (2003) Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9: 4116–4124.
30. Yen RW, Verrino PM, Neakin BD, Yu JJ, el-Deiry W, et al. (1992) Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res 20: 2297–2299.
31. Pan G, Thomson JA (2007) Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res 17: 42–49.
32. Hassiori N, Inao Y, Nishino K, Ohgane J, Yagi S, et al. (2007) Epigenetic regulation of Nanog gene in embryonic stem and trophoblast stem cells. Genes Cells 12: 387–396.
33. Rodda DJ, Chew JH, Lim LH, Loh YH, Wang B, et al. (2005) Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem 280: 24731–24737.
34. Zhu Z, Wu G, Wei H, Yang H, He Y, et al. (2012) Investigation of the permeability and optical clearing ability of different analytes in human normal and cancerous breast tissues by spectral domain OCT. J Biophotonics 5: 536–543.